| Nov 19 |
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
|
| Nov 16 |
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
|
| Nov 12 |
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options
|
| Nov 7 |
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
|
| Nov 6 |
BioMarin to Participate in Three Upcoming Investor Conferences
|
| Nov 5 |
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
|
| Nov 4 |
BioMarin (BMRN) Upgraded to Buy: Here's Why
|
| Nov 4 |
BMRN vs. INCY: Which Stock Is the Better Value Option?
|
| Nov 1 |
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
|
| Oct 31 |
BioMarin price target raised to $106 from $104 at UBS
|
